

EMBOTAPE

ORAL PASTE 40% W/W

Each 28.5g syringe contains 11.4g pyrantel embonate

DATA
SHEET



INDICATIONS

Embotape Oral Paste 40% w/w is a broad spectrum anthelmintic for horses, containing pyrantel embonate.

For use in the horse for the control and treatment of adult large and small strongyles, pinworms, roundworms and tapeworms.

BENEFITS

- Broad spectrum activity of pyrantel embonate
- Calibrated syringe for accurate dosing



LIST No	UNIT PACKAGE	CASE SIZE
1EMB004	28.5g Syringe	10

See reverse for Administration & Dosage

Embotape

Oral Paste 40% w/w

Each 28.5g syringe contains 11.4g pyrantel embonate



PRESENTATION

Pale yellow to buff-coloured oral paste. Each 28.5g syringe contains 11.4g pyrantel embonate.

TARGET SPECIES

Horses and Ponies.

INDICATIONS FOR USE

Pyrantel embonate is indicated for use in the horse for the control and treatment of adult infections of large and small strongyles, Pinworms, Roundworms, Tapeworms.

Pyrantel embonate has broad spectrum activity, including activity against:

Large strongyles: *Strongylus vulgaris*, *S. edentatus*, *S. equinus*.

Small strongyles: *Trichonema* spp. (Cyathostomes), *Triodontophorus* spp.

Pinworms: *Oxyuris equi*, *Probstmayria vivipara*.

Large roundworms: *Parascaris equorum*.

Tape worms: *Anoplocephala perfoliata*.

CONTRAINDICATIONS

Not for use in foals less than 4 weeks of age.

Contraindicated in known sensitivity to pyrantel and in severely debilitated animals.

SPECIAL WARNINGS FOR TARGET SPECIES

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.

- Underdosing, which may be due to underestimation of weight or misadministration of the product.

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Resistance to pyrantel has been reported in cyathostomes in horses (also widespread in the USA and Canada). Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

SPECIAL PRECAUTIONS FOR USE IN ANIMALS

The same syringe should only be used to dose two animals if they are both healthy and are either running together, or are on the same premises and in direct contact with each other.

SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE PRODUCT

Direct contact with the skin should be avoided.

Wash hands and any other parts of the body which comes into contact with the product after use.

Avoid handling the product if you know you are hypersensitive to pyrantel.

ADVERSE REACTIONS

Pyrantel embonate is safe for horses and ponies of all ages, including foals older than 4 weeks old, pregnant mares and stallions. Impaction of the small intestine may occur in foals, infected with high numbers of *Parascaris equorum*. Symptoms (colic) may be seen as soon as 30 minutes after treatment

USE DURING PREGNANCY AND LACTATION

Embotape is safe to administer to pregnant and lactating mares provided the recommendations are followed.

INTERACTIONS WITH OTHER MEDICINAL PRODUCTS

Combined administration of pyrantel and levamisole or piperazine is not recommended.

AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE

Control and treatment of Strongyles, Pinworm and Large Roundworm.

Embotape should be used at a dose rate of 19 mg pyrantel embonate per kg bodyweight.

The prescribed amount of Embotape is deposited on the tongue of the animal and the animal allowed to swallow. The complete contents of one syringe contains 11.4g pyrantel embonate (6 graduated doses of 1.9g) in 28.5g paste and is sufficient for the treatment of 600kg bodyweight. Each graduation of the syringe is sufficient for the treatment of 100kg body-weight.

Practical Dosage Recommendations

Weight	Type	Routine Treatment
Up to 100 kg	Miniature ponies	Syringe mark 100 kg
101 – 300 kg	Donkey, Shetland and other small ponies, foals	Syringe mark 300 kg (1/2 syringe)
301 – 400 kg	Dartmoor, New Forest, Welsh	Syringe mark 400 kg
401 – 500 kg	Light hunters, Arabs, etc	Syringe mark 500 kg
501 – 600 kg	Thoroughbreds	Syringe mark 600 kg (1 syringe)
601 kg and over	Heavy hunters, draught horses	1 full syringe plus additional 100 kg syringe marks for each extra 100 kg bodyweight.

Control and treatment of Tapeworm

Embotape should be used at a dose rate of 38mg pyrantel embonate per kg bodyweight (i.e. twice the dose used for strongyles). To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked. Inappropriate use of anthelmintics may increase resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on professional advice and take into account current best practice recommendations for parasite control.

In all treatment cases, to ensure administration of a correct dose, body weight should be determined as accurately as possible.

OVERDOSE

Pyrantel embonate is of low oral toxicity. Oral doses of up to 2000mg/kg bodyweight in mice and rats and 1000mg/kg in dogs have produced no evidence of toxicity.

Pyrantel embonate, at dosages of up to 60mg/kg bodyweight, had no adverse effects on horses, ponies or foals. Monitoring included haematological parameters, serum cholinesterase and glutamic oxaloacetic transaminase levels.

WITHDRAWAL PERIODS

Not to be used in horses and ponies intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

PHARMACOLOGICAL PROPERTIES

Pyrantel embonate is a broad spectrum anthelmintic with a depolarising neuromuscular blocking action which results in spastic paralysis of the worm, and their expulsion from the intestinal tract. Pyrantel embonate also inhibits cholinesterases which contributes to its neuromuscular effects. Pyrantel embonate is poorly absorbed from the gastrointestinal tract, making it suitable for use as an intestinal anthelmintic. The small amount of pyrantel embonate which is absorbed is quickly metabolised with little being excreted intact.

EXCIPIENTS

Butylated Hydroxytoluene, Polysorbate 80, Silica Colloidal Anhydrous, Maize Oil

SHELF LIFE

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

STORAGE

Do not store above 25°C. Protect from direct sunlight.

DISPOSAL

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

LEGAL CATEGORY

POM-VPS

MARKETING AUTHORISATION NUMBER

Vm 50146/4014

MARKETED IN THE UK BY

Bimeda UK

Unit 2, Bryn Cefni Industrial Park
Llangefni, Anglesey, Wales, LL77 7XA
01248 725400

Use Medicines Responsibly.

Noah.co.uk/responsible

TAKE TIME



OBSERVE LABEL
DIRECTIONS

Bimeda data sheet created: July 2025